Alkermes发布发作性睡病中期alixorexton数据

2026-06-18 05:07

Alkermes reported positive phase 2 study results of alixorexton for narcolepsy type 2 after Wednesday's market close.
The Vibrance-2 trial met its dual primary endpoints: improvement from baseline compared to placebo on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale at week eight.
Patient-reported improvements in wakefulness were maintained through a five-week open-label extension.
Also, those on alixorexton saw improvements from baseline in fatigue compared to those taking placebo. No serious treatment-emergent adverse events were reported.
Alkermes said it has begun a phase 3 program examining once-daily and split dose regimens of the asset,
Alixorexton is considered an oral selective orexin 2 receptor agonist.

More on Alkermes